Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes

NCT02449603 · Completed

Last updated 2026-05-28

This clinical trial compared the effects of exenatide and biphasic insulin aspart 30 on blood sugar fluctuations in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 150 people

Who can join Ages 18–70 · all sexes

Timeline Started 2015-11 · est. completion 2018-04

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT02449603 ↗

Description as written by the study sponsor.

This is a multi-centre, open-label, randomized, parallel trial to compare the effect of Exenatide versus Biphasic insulin Aspart 30 on glucose variability and inflammatory markers in type 2 diabetes mellitus (T2DM) patients inadequately controlled with metformin monotherapy.

Treatments tested

Exenatide also known as Byetta Drug
Biphasic insulin Aspart 30 Drug

Main thing measured	Change of mean amplitude of glycemic excursions
Sponsor	Xijing Hospital
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02449603 ↗